Page 16 - Erişkinlerde Hastanede Gelişen Pnömoni Tanı ve Tedavi Uzlaşı Raporu

Türk Toraks Derneği Erişkinlerde Hastanede Gelişen Pnömoni Tanı ve Tedavisi Uzlaşı Raporu

12. Yalçın A, Şen E, Erol S, ve ark. Solunum yoğun bakım ünite- 32. File MT, Barlett JG, Bond S. Epidemiology, pathogenesis, microbi-
mizdeki enfeksiyon etkenleri ve direnç sorunu. Ortadoğu Tıp ology, and diagnosis of hospital-acquired and ventilator-associ-
Dergisi 2013;5:17-24. ated pneumonia in adults. https://www.uptodate.com/contents/
13. Ok G, Hörü G, Tok D, ve ark. Celal Bayar Üniversitesi Anestezi epidemiology-pathogenesis-microbiology-and-diagnosis-of-
Yoğun Bakım Ünitesi’nde Hastane İnfeksiyonlarının Sürveyansı. hospital-acquired-and-ventilator-associated-pneumonia-in-
Yoğun Bakım Dergisi 2007;7:452-7. adults.2017.
rd
14. Lynch JP 3 . Hospital acquired pneumonia: Risk factors, micro- 33. Hurley JC. Worldwide variation in incidence of Acinetobacter
biology and treatment. Chest 2001; 119:373S-84S. associated ventilator associated pneumonia: a meta regression.
15. Avcı M, Özgenç O, Coşkuner A, et al. Hospital-acquired BMC Infect Dis 2016;16: 577.
pneumonia in nonintensive care unit wards. Turk J Med Sci 34. Rosenthal VD, Al-Abdely HM, El-Khaly AA, et al. International
2010;40:357-363. Nosocomial Infection Control Consortium report, data sum-
16. Rello J. Bench-to-bedside review: Therapeutic options and issu- mary of 50 countries for 2010-2015: Device associated module.
es in the management of ventilator-associated bacterial pneu- Am J Infect Control 2016;44:1495-504.
monia. Critical Care 2005;9:259-65. 35. Özvatan T, Akalın H, Sınırtaş M, et al. Nosocomial Acinetobac-
17. Magill SS, Edwards JR, Fridkin SK, et al. Survey of health care- ter pneumonia: Treatment and prognostic factors in 356 cases.
associated infections. N Engl J Med 2014;370:2542-3. Respirology 2016;21:363-9.
18. Esen S, Leblebicioglu H. Prevalence of nosocomial infections at 36. Çakar A, Akyön Y, Gür D, et al. Investigation of carbapenemases
intensive care units in Turkey: a multicentre 1-day point preva- in carbapenem-resistant Escherichia coli and Klebsiella pneu-
lence study. Scand J Infect Dis 2004;36:144-8. moniae strains isolated in 2014 in Turkey. Mikrobiyol Bul 2016;
19. American Thoracic Society, Infectious Diseasee Society of Ame- 50:21-33.
rica Guidelines for the management of adults with hospital ac- 37. İnan A, Özgültekin A, Akçay SS, et al. Alterations in bacterial
quired, ventilator associated, and health care associated pneu- spectrum and increasing resistance rates in isolated microor-
monia. Am J Respir Crit Care Med 2005;171:388-416. ganisms from device-associated infections in an Intensive Care
20. Rosenthal VD, Bijie H, Maki DG, et al. International Nosocomial Unit of a teaching hospital in Istanbul, Turkey. Jpn J Infect Dis
Infection Control Consortium (INICC) report, data summary of 2012;65:146-51.
36 countries, for 2004-2009. Am J Infect Control 2012;40:396- 38. Tükenmez Tigen E, Doğru A, Koltka EN, et al. Device associated
407. nosocomial infection rates and distribution ofantimicrobia resis-
21. Rosenthal VD, Maki DG, Mehta Y, et al. International Nosoco- tance in a medical surgical intensive care unit in Turkey. Jpn J
mial Infection Control Consortiu (INICC) report, data summary Infect Dis 2014; 67: 5-8.
of 43 countries for 2007-2012. Device-associated module. Am 39. Mirza HC, Sancak B, Gür D. The Prevalence of Vancomycin-
J Infect Control 2014;42:942-56. Intermediate Staphylococcus aureus and Heterogeneous VISA
22. Leblebicioglu H, Erben N, Rosenthal VD, et al. International Among Methicillin-Resistant Strains Isolated from Pediatric Po-
Nosocomial Infection Control Consortium (INICC) national re- pulation in a Turkish University Hospital. Microb Drug Resist
port on device-associated infection rates in 19 cities of Turkey, 2015;21:537-44.
data summary for 2003-2012. Ann Clin Microbiol Antimicrob 40. Hyo-Lim Hong, Sang-Bum Hong, Gwang-Beom Ko, et al. viral
2014;13:51. infection is not uncommon in adult patients with severe hospi-
23. Dudeck MA, Horan TC, Peterson KD, et al. National Healthcare tal-acquired pneumonia. PLoS One 2014;9:e95865.
Safety Network report, data summary for 2011, device associa- 41. Micek ST, Chew B, Hampton N, et al. A case-control study as-
ted module. Am J Infect Control 2013;41:286-300. sessing the impact of non-ventileted hospital acquired pneumo-
24. Koulanti D, Tsigou E, Rello J. Nosocomial pneumonia in 27 nia on patient outcomes. Chest 2016;150:1008-14.
ICUs in Europe: perspectives from EU-VAP/CAP study. Eur J Clin 42. Perlroth J, Choi B, Spellberg B. Nosocomial fungal infec-
Microbiol Infect Dis 2017;36:1999-2006. tions: epidemiology, diagnosis, andtreatment. Med Mycol
25. Wang Y, Eldridge N, Metersky ML, et al. National trends in pa- 2007;45:321-46.
tient safety for four common conditions, 2005-2011. N Engl J 43. Griffin M, Kosmisky DE, Templin MA, et al. Antifungal use in
Med 2014;370:341-51. immunocompetent, critically ill patient with pneumonia does
26. Türkiye Cumhuriyeti Sağlık Bakanlığı Türkiye Halk Sağlığı Kuru- not improve clinical outcomes. Heart&Lung 2016;45:538-43.
mu Mikrobiyoloji Referans Laboratuarı Daire Başkanlığı Ulusal 44. Albert M, Williamson D, Muscedere J, et al. Candida in the res-
Hastane Enfeksiyonları Sürveyans Ağı Özet Raporu 2014, Mayıs piratory tract secretions of critically ill patients and the impact
2015, 1-32. of antifungal treatment: a randomized placebo controlled pilot
27. Türkiye Cumhuriyeti Sağlık Bakanlığı Türkiye Halk Sağlığı Kuru- trial (CANTREAT study). Intensive Care Med 2014;40:1313-
mu Mikrobiyoloji Referans Laboratuarı Daire Başkanlığı Ulusal 22.
Hastane Enfeksiyonları Sürveyans Ağı Özet Raporu 2015, Ağus- 45. Eggimann P, Bille J, Marchetti O. Diagnos of invasive candidiasis
tos 2016, 1-43. in the ICU. Ann Intensive Care 2011;1:37.
28. Tağrıkulu H, Memiş D, İnal MT, Turan N. yoğun bakım hastala- 46. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resis-
rında ventilatör ilişkili pnömoni insidansının araştırılması. J Turk tant, extensively drug-resistant and pandrug-resistant bacteria:
Soc Intens Care 2016;14:28-38. an international expert proposal for in terim standart definitions
29. Sevinç C, Şahbaz C, Uysal Ü, et al. Hastane kökenli pnömoni for acquired resistance. Clin Microb Infect 2012;18:268-81.
olgularında etken dağılımı ve prognoza etkili faktörler. Tüberkü- 47. Canton R, Ruiz-Garbajosa P. Co-resistance: an opportunity
loz Toraks 2007;55:153-9. for the bacteria and resistance genes. Curr Opin Pharmacol
30. Melsen WG, Rovers MM, Groenwold RH, et al. Attributablo 2011;11:477-85.
mortality of ventilator- associated pneumonia: a meta-analysis 48. DiPasquale M, Aliberti S, Mantero M, et al. Non-intensive care
of individual patient data from randomised prevention studies. unit acquired pneumonia: A new clinical entity? Int J Mol Sci
Lancet Infect Dis 2013;13:665-71. 2016;17:287.
31. Ağırbaş İ. Hastane İnfeksiyonları maliyet analizi. Ankara Üni- 49. Scheld WM. Developments in the pathogenesis, diagnosis and
versitesi Bilimsel Araştırma Projeleri 2013. http://acikarsiv.anka- treatment of nosocomial pneumonia. Surg Gynecol Obstet
ra.edu.tr/browse/24778 1991;172 Suppl: 42-53.